Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) in adults, data on safety and efficacy in pediatric patients are scarce. We report the use of InO in 51 children with relapsed/refractory ALL treated in the compassionate use progr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia
Hauptverfasser: Bhojwani, Deepa, Sposto, Richard, Shah, Nirali N., Rodriguez, Vilmarie, Yuan, Constance, Stetler-Stevenson, Maryalice, O’Brien, Maureen M., McNeer, Jennifer L., Quereshi, Amrana, Cabannes, Aurelie, Schlegel, Paul, Rossig, Claudia, Dalla-Pozza, Luciano, August, Keith, Alexander, Sarah, Bourquin, Jean-Pierre, Zwaan, Michel, Raetz, Elizabeth A., Loh, Mignon L., Rheingold, Susan R.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group UK 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6438769/
https://ncbi.nlm.nih.gov/pubmed/30267011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-018-0265-z
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge